Figure 2.
Maximum local and systemic toxicity experienced during the trial per patient divided by dose. The vaccine well tolerated with a single grade 3 systemic toxicity event
Maximum local and systemic toxicity experienced during the trial per patient divided by dose. The vaccine well tolerated with a single grade 3 systemic toxicity event